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In this review, we will discuss the evidence and provide an update on the 
pharmacological treatments of Behavioural and Psychological symptoms of 
Dementia (BPSD) especially anti-psychotic medications.  Non-
pharmacological management of BPSD remains the initial treatment for 
BPSD; however, pharmacological management have a role in specific 
situations.  This review should support the management of elderly inpatients 
suffering from Dementia and challenging behaviour in mental health units, 
general hospitals, community settings and care homes. It will help in raising 
awareness to the risk of complications such as stroke/death associated with 
first and second generation antipsychotic medications. It will also highlight 
some issues in relation to the current guidelines and licensing in the USA, UK 
and Europe. Good clinical practice used in the management of BPSD to 
reduce the risk of stroke and other complications is included. 
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What is BPSD? 
Dementia is a progressive and largely irreversible clinical syndrome 
characterised by widespread impairment of mental function.1 Behavioural and 
Psychological symptoms of Dementia (BPSD) is a term introduced in the 
1990s,2 with an estimated incidence of up to 75% of people with Dementia 
may be affected by non-cognitive symptoms and challenging behaviour.1 
Dementia patients can experience changes in personality, self-neglect, 
apathy, depression, aggression, restlessness, wandering and disruptive vocal 
activity, sleep disturbance, and disinhibited sexual behaviour. Table 1 
summarises BPSD frequency depending on Alzheimer’s disease (AD) stages; 
the domains were evaluated using the Neuro Psychiatric Inventory.  
Table 1: Frequency of BPSD across AD stages 
 Mild* Moderate ** Severe* 
Apathy 47% 67% 92% 
Agitation 47% 45% 85% 
Aberrant Motor 12% 53% 84% 
Depression 12% 52% 62% 
Anxiety 24% 49% 54% 
Irritability 35% 35% 54% 
Delusions 12% 37% 31% 
Disinhibition 35% 22% 31% 
Hallucinations 12% 24% 8% 









Apathy is a disorder of motivation that persists over time; its formal diagnosis 
requires the following criteria:  Diminished motivation for at least four weeks, 
two of the three dimensions of apathy (reduced goal-directed behaviour, goal-
directed cognitive activity and emotions). These symptoms result in functional 
impairment; not exclusively explained by physical disability or a substance 
effects.5  
It appears that Depression, Apathy, Delusions, Anxiety and agitation are more 
frequent in severe compared to mild Dementia; while hallucinations less 
frequent in severe compared to moderate Dementia (Table 1).  
Sexually disinhibited behaviours are common, with prevalence between 2-
17%, with almost equal frequency in men and women.6 These may include 
explicit sexual comments, exposing the breasts or genitals in public, touching 
someone inappropriately; while some behaviour still ambiguous such as 
undressing outside the bathroom or bedroom. There is no widely agreed 
definition for an abnormal sexual behaviour in Dementia and is based on 
judging what is normal for a person in a particular situation. Accordingly, there 
is a difference based on the setting; for example if the patient is at home, a 
residential home or in hospital depending on the level of risk or discomfort on 
others.6 
People suffering from BPSD should be offered an assessment at an early 
opportunity including physical health, depression, undetected pain, medication 
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adverse effects, psychosocial factors.1 Individually tailored care plans should 
be developed, recorded in the notes and reviewed regularly.1  
Can certain drugs increase BPSD risk? 
Medications with anticholinergic activities have a potential to cause symptoms 
of BPSD such as delirium and confusion. These medications include Tricyclic 
antidepressants, first generation antipsychotics, urinary retention medications 
like oxybutynin, H2-antagonists such as cimetidine and antibiotics such as 
quinolones, anticonvulsants such as carbamazepine. Furthermore, some 
medications are known to be associated with side effects such as an increase 
the risk of depression with as B-blockers and anticonvulsants. Drugs causing 
Psychosis symptoms include systemic steroids, NSAIDS.7 
Can the pharmacological management be the first response 
to BPSD? 
Non-Pharmacological management should be the first response. However, 
pharmacological treatment may be an appropriate first response if there is a 
specific indication; for example; Psychosis or depression, severe symptoms, 
distressing to patients or others and treatment is urgently needed and the 
behaviour has no clear situational trigger or occurs in a setting where carers 
cannot cope.8 In addition, pharmacological treatment has a role if there is an 
immediate risk of harm to the patient or others.1 There is a need for carers in 
care homes to have further Dementia training; for example a recent primary 
survey in the west Midlands on Perceptions about the levels of dementia 
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training among staff in dementia registered care homes identified that 
19 % of staff that participated in the survey felt that further training is 
needed in Behavioral and Psychological symptoms of Dementia 57 
Antipsychotics used to treat BPSD are arbitrarily divided into typical (first 
generation) and atypical (second generation). Antipsychotics block Dopamine 
(DA) receptor in the mesolimbic, mesocortical and the therapeutic efficacy is 
thought to correlate with their affinity for D2-receptors, although other 
mechanisms are likely to contribute. The binding to the basal ganglia and 
pituitary glands D2-receptors lead to their extensive side effects.  
Atypical antipsychotics such as olanzapine have a relatively low affinity for 
D2-receptors, which does not correlate with their clinically effective dose. 
They are 5-HT2 and D4-receptors antagonists with effectiveness in physical 
aggression, agitation and psychosis. 9-11 There is a modest but significant 
effectiveness in treatment of aggression in AD.12  
On the other hand, there was concern regarding the safety of administering 
atypical antipsychotics to elderly as shown in the Committee on Safety of 
Medicines (CSM) alert on atypical antipsychotic use in BPSD patients.13 This 
followed manufacturer data, which showed an increased risk of 
cerebrovascular adverse events ranging from transient ischemic attacks to 
strokes with risperidone and olanzapine. The CSM suggested a three-fold 
increased risk of cardiovascular adverse effects from 1.1%-3.3% over 12-
week period. In addition, risperidone is associated with additional risk of death 
when co-prescribed with furosemide.14  
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The Faculty of Old Age Psychiatry issued guidance with the British Geriatrics 
Society, the Royal College of General Practitioners and the Alzheimer’s 
Society on atypical antipsychotics use in BPSD patients.8 Since then, there 
were reports that patients had their medication inappropriately withdrawn or 
switched.8 Furthermore, there were pharmaceutical issues such as 
polypharmacy with the prescribing of several antipsychotics concurrently or 
medications administered at high doses even exceeding the BNF limits or 
medications given for too long without reviewing the need or the dose.15 The 
use of antipsychotics appears to be associated with accelerated cognitive 
decline in people with AD.16 
Risk of death from prescribing antipsychotics 
The Food and Drugs Administration (FDA) concluded that labelling for all 
atypical antipsychotics should include information regarding the increased risk 
of mortality in dementia. This was based on a meta- analysis of 17 placebo-
controlled trials of four atypical antipsychotics. These trials showed the risk of 
death in the drug-treated patients was 1.6 to 1.7 times higher compared to 
placebo. The main causes of deaths appeared either cardiovascular or 
infections. Because of the results consistency, the FDA concluded that the 
effect is likely related to the common pharmacologic effects of atypical 
antipsychotics, including those not included in the meta-analysis.17 
Around 180,000 dementia patients are treated with antipsychotics in the UK 
per year, up to 36,000 may benefit from the treatment. In terms of negative 
effects directly attributable to antipsychotics, use at this level equates to 
additional 1,800 deaths and 1,620 cerebrovascular adverse events. The 
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proportion of these prescriptions which would be unnecessary if appropriate 
support were available is unclear.18 There were significant changes in the 
management of BPSD using antipsychotics since the publication of the 
Banerjee report.  
Are conventional antipsychotics safer? 
Typical antipsychotics are relatively less effective at controlling schizophrenia 
negative symptoms. Two large observational and epidemiological studies 
examined the risk of death in patients on conventional antipsychotics. The first 
study included 27,259 subjects with a diagnosis of dementia and compared 
the risk for death with atypical antipsychotic versus no antipsychotic or 
conventional antipsychotic. Conventional antipsychotics use showed a 
marginally higher risk of death compared with atypical antipsychotics.19 
Another study included 37,241 subjects, prescribed either conventional or 
atypical antipsychotics and demonstrated that the risk of death with 
conventional antipsychotics was comparable, and possibly greater than 
atypical antipsychotics.20 Due to methodological limitations, FDA highlighted 
that these results preclude any conclusion that conventional antipsychotic 
medications have a greater risk of death. However, FDA determined that the 
overall weight of evidence indicated that conventional antipsychotics share 
the increased risk of death observed for atypical antipsychotics.21 
FDA notified healthcare professionals that conventional and atypical 
antipsychotics are associated with an increased risk of mortality in elderly 
patients and requires manufacturers to make safety-label changes (Table 2). 
FDA and NICE recommend physicians, who prescribe antipsychotics to 
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discuss the risk of increased mortality with their dementia patients, patients’ 
families and caregivers. 
Table 2: Drugs with safety-labels changes  
Typical Antipsychotic Drugs Atypical Antipsychotic Drugs 
Prochlorperazine                       Aripiprazole 
Haloperidol  Clozapine 
Loxapine     Ziprasidone (unlicensed in the UK) 
Thioridazine   Paliperidone 
Molindone Risperidone 
Thiothixene   Quetiapine 
Pimozide         Olanzapine 
Fluphenazine            
Trifluoperazine                  
Chlorpromazine     
Perphenazine   
The Committee for Medicinal Products for Human Use concluded there is 
ample evidence that conventional antipsychotics are associated with an 
increase the risk of death in dementia.22 European Medicines Agency 
highlighted in addition to the FDA evidence that ten further publications 
showed the risk of death associated with conventional antipsychotics. Seven 
of them concluded that conventional antipsychotics are associated with 
Comment [AA1]: Table 2 has been removed due 
to the word limit and as suggested by the reviewer 
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increased mortality, whilst three concluded that neither atypical nor 
conventional antipsychotics are associated with increased mortality.22 
Licensing and Guidelines in the UK: 
In the UK, there is no drug currently licensed specifically for BPSD 
management.8 Risperidone is licensed for short term treatment (up to six 
weeks) of persistent aggression in moderate to severe AD unresponsive to 
non-pharmacological interventions and when there is a risk to harm.23 This 
appears to contradict with the evidence that antipsychotics are associated 
with increased risk of stroke as early as thirty days of treatment.19 
Anti-Dementia drugs licensed for cognition treatment not behaviour; 
cholinesterase inhibitors are licensed for mild to moderate AD, rivastigmine for 
mild to moderate Parkinson’s Disease Dementia (PDD).24 The only drug 
currently used for severe AD is memantine.1 Donepezil inhibits 
acetylcholinesterase with side effects such as cardiac arrhythmia; 
gastrointestinal disturbances; pancreatitis, stroke, seizure, delirium, vivid 
dreams, insomnia.  Memantine is a non-competitive NMDA antagonist as 
excessive glutamate excitotoxicity is implicated in dementia. 
What evidence supports use of Pharmacological alternatives? 
Anti-dementia medications may have a beneficial effect on some behavioural 
symptoms. 25-27 Cholinesterase inhibitors efficacy was demonstrated in 
several large RCTs 26-28 as they reduce psychotic symptoms in dementia and 
can be a good alternative to antipsychotics. 
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Current guidelines state AD patients with non-cognitive symptoms and/or 
challenging behaviour may be offered cholinesterase inhibitor if non-
pharmacological approach and antipsychotics were inappropriate or 
ineffective.1 However, for vascular dementia patients, the current guidelines 
do not recommend these medications except as part of clinical studies.1  
The Faculty of Old Age Psychiatry health technology appraisal recognised the 
adverse-effects associated with antipsychotics and highlighted the benefits of 
cholinesterase inhibitors and memantine. It urged NICE to ensure these 
medications are not so restricted leading clinicians to consider the use of 
antipsychotics. The faculty suggested memantine should be recommended as 
a treatment option for patients with moderate to severe AD where there are 
prominent behavioural symptoms not managed by non-pharmacological 
means and when alternative therapeutic options would involve high risk.8  
In NICE guidance, cholinesterase inhibitors are options for managing mild and 
moderate AD, while memantine for moderate AD people who cannot take 
cholinesterase inhibitors and severe AD.1 Patients on memantine were slightly 
less likely to develop agitation (12% vs 18% in the control group). 29 
Anticonvulsants: 
Limited evidence suggests lamotrigine may be helpful for agitation and 
psychosis in dementia.30 Lamotrigine is an antiepileptic whose mechanism of 
action is linked to voltage-sensitive sodium-channel blockade in the neuronal 
membrane and inhibition of glutamate and aspartate release.31 Lamotrigine 
has good concordance, acceptable side-effects margin, however a rash on 
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initiation can influence adherence/continuation, and no worsening in the 
cognitive functions.31 Large clinical trials are required to confirm Lamotrigine 
positive clinical outcome. Carbamazepine acts on sodium-channels with 
demonstrated efficacy in agitation treatment.32  Gabapentin, a structural 
analogue of GABA, has shown efficacy in the management of behavioural 
symptoms in AD.33, 34 There is no enough evidence to support the use of 
valproic acid in the management of BPSD and even suggest that caution is 
needed. 35 
Selective Serotonin Reuptake Inhibitors (SSRI) 
SSRI are the first line in depression treatment, include fluoxetine, citalopram, 
escitalopram, paroxetine, and sertraline. SSRIs possess a relative 
advantageous safety profile with similar efficacy to TCAs; they inhibit 
serotonin reuptake through 5-HT transporters; SSRIs lack significant 
cardiotoxicity (except citalopram) with less anti-muscarinic, anti-adrenergic 
properties. Citalopram has shown efficacy in AD patients in reducing agitation 
and caregiver distress in combination with psychosocial intervention. 36 
However, efficacy in treating depression in dementia is not fully supported. 37 
SSRIs can cause sexual dysfunction, GI distress, bleeding complications and 
rarely serotonin syndrome. Serotonergic deficits in AD contribute to verbal 
and physical aggression, sleep disturbance, depression and psychosis.38 
Common 5-HT receptor polymorphisms have been associated with visual 
hallucinations in AD; 39 aggression and psychosis in AD were associated with 
5-HT transporters polymorphisms.40  
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Psychotic symptoms in AD are distinct from schizophrenia; 61% of patients 
experiencing hallucinations had only visual hallucinations.41  Delusions in 
dementia may result from misperceptions and impaired judgment. 
Consequently, delusions in AD may be attenuated by SSRI anxiolytic effect.42  
Citalopram was efficacious in the short-term treatment of BPSD in dementia.43 
European Data from different countries including Switzerland, Germany and 
Austria suggested SSRI a first-line in about 30% of BPSD patients.44  
Trazodone blocks 5-HT2A and 5-HT2C receptors and inhibits serotonin 
transporter, showed efficacy in controlling BPSD (a randomised controlled 
trial, a case series and other smaller studies),45, 46 however another study 
suggested that its efficacy was similar to placebo.47  
Pharmacological Treatment of Sexually disinhibited 
behaviours  
There are no drugs currently licensed in the UK for sexually disinhibited 
behaviours; neuroleptics, anti-androgens, oestrogens, LHRH analogues, 
Serotonergicsserotonergics, Gabapentin gabapentin are occasionally used 
off-license.6 There is a scarce evidence for Neuroleptics. Citalopram and 
paroxetine, with a relatively safe profile, are associated with improvement in 
sexual aggression and disinhibition.48 Clomipramine, a TCA that inhibits 
serotonin and noradrenaline reuptake, was effective.49 However, there are 
issues that need reviewing before recommending clomipramine as there is 
increased risk of falls and worsening confusion. 
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Cimetidine, a H2-antagonist was associated with a reduction in libido and 
hypersexual behaviour in 14 out of 20 patients without remarkable side-
effects. The other patients responded to combinations of cimetidine with 
ketoconazole, spironolactone; however the safety profile of using these 
combinations should be appropriately reviewed.50 
Gabapentin showed a reduction in agitation and inappropriate sexual 
behaviour in vascular Dementia51 and AD.52 
Little is known about oestrogens and LHRH analogues; and there are no 
controlled studies for anti-androgens for the treatment of sexual disinhibition 
in dementia 53 but they were used in sexual offenders.6  There are few reports 
on oestrogens for treating hypersexuality associated with dementia, however 
more robust evidence is needed, and especially that oestrogen use is 
associated with cardiovascular-related deaths.53 
Discussion: 
Early Data in a survey for Old Age psychiatrists showed that most of the 
respondents (95.5%) disagreed with the statement that antipsychotics should 
never be prescribed for patients with dementia and all reported that they 
prescribed antipsychotics for BPSD management.54 
In light of the risk of death with conventional and atypical antipsychotics and 
their financial implications, antipsychotic medications should be avoided. This 
may apply after failure of non-pharmacological methods to manage BPSD, 
provided that there is evidence for safer pharmacological alternatives. 
However more robust studies are needed to validate the effectiveness and 
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safety of the alternatives medications especially that they appear to be cost-
effective. There are challenges in the assessment and treatment of patients 
with Behavioural and Psychological symptoms of Dementia and consequently 
a tailored care plan will be needed for each patient based on a person centred 
approach and especially depending on an identifiable symptom that needs to 
be treated.  
Withdrawal of antipsychotics improves functional and cognitive status in AD 
patients and can be achieved successfully in people relatively free from 
behavioural symptoms for at least 3 months.55 However, it is prudent to 
withdraw antipsychotics cautiously and gradually except for specific and 
distressing medications side-effects.  On the other hand, not everyone on 
atypical antipsychotics should have their drug stopped or changed as BPSD 
can persist in the long-term and often resistant to treatment. Atypical 
antipsychotics can be continued if severe adverse consequences may occur 
(or have occurred) if the medications are discontinued or when no alternative 
treatment approaches suitable.  
Is there a need for local protocols for the management of 
BPSD? 
There is conflicting information from different sources such as academic 
literature, Pharmaceutical industry, guidelines, Health Trusts policies, local 
experts and licensing authorities regarding the appropriate management of 
BPSD using pharmacological treatments.  
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National Guidelines are expected to be influential and safe. Evidence-based 
approach sees the bigger picture and is politically neutral with less risk of 
bias, but is time consuming. Local expert opinion can vary widely and may be 
influenced by local pharmaceutical exposure and is considered not cost-
effective with protocols for prescribing, monitoring need to be introduced. 
Some hospitals developed local protocols with algorithms and flow charts 
suggesting first and second lines in BPSD pharmacological treatment.  
Algorithms use graphic representation for a logical scientific approach to a 
clinical problem. If wisely administered, algorithms have a role in patients-care 
and cost-effectiveness.  However a valid criticism centres on its rigidity and 
the automatic approach that fosters within the clinical field, by neglecting 
individual factors, especially when such algorithms are poorly applied.56 The 
guidelines do not override healthcare professionals’ responsibility to make 
appropriate decisions depending on the patients’ circumstances, in 
consultation with the patient and/or their carer.1 
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